Amgen Inc. $AMGN Shares Sold by KG&L Capital Management LLC

Key Points

• KG&L Capital Management cut its Amgen stake by 76.0% in Q4, selling 9,535 shares and finishing the period with 3,010 shares worth about $985,000, while institutional investors collectively own 76.5% of the company.
• Amgen reported a quarterly EPS beat ($5.29 vs. $4.76), set FY2026 guidance at 21.600–23.000 EPS, received China approval for lung‑cancer drug tarlatamab, and announced a quarterly dividend of $2.52 (annualized $10.08, ~2.9% yield), with mixed analyst price‑target changes supporting near‑term sentiment.

KG&L Capital Management LLC lowered its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 76.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,010 shares of the medical research company's stock after selling 9,535 shares during the period. KG&L Capital Management LLC's holdings in Amgen were worth $985,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Board of the Pension Protection Fund acquired a new stake in shares of Amgen during the fourth quarter worth about $26,000. Olistico Wealth LLC acquired a new stake in shares of Amgen during the fourth quarter worth about $33,000. Cloud Capital Management LLC acquired a new stake in shares of Amgen during the third quarter worth about $34,000. Saranac Partners Ltd acquired a new stake in shares of Amgen during the third quarter worth about $37,000. Finally, Holos Integrated Wealth LLC acquired a new stake in shares of Amgen during the fourth quarter worth about $37,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: China approval for tarlatamab expands Amgen’s lung-cancer market access and supports future revenue in a large oncology market — a meaningful commercial win for a new oncology asset. Amgen's lung cancer drug tarlatamab wins China approval
• Positive Sentiment: Phase‑4 FORWARD II gout study update: a less‑frequent Krystexxa dosing schedule could improve patient adherence and lifetime drug value, which would be positive for product uptake and revenue stability. Amgen’s FORWARD II Gout Study
• Positive Sentiment: Analyst bullishness on fundamentals: Zacks argues Amgen is poised to beat earnings again, supported by its recent history of surprise results and solid guidance — this can underpin near‑term sentiment ahead of the next report. Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again
• Positive Sentiment: Royal Bank of Canada raised its price target to $370, signaling upside from some institutional analysts and suggesting conviction in Amgen’s mid‑term growth drivers. Royal Bank Of Canada Increases Amgen Price Target
• Neutral Sentiment: Guggenheim nudged its target to $351 while retaining a neutral rating — little immediate directional impact given the price is near that level. Amgen Price Target Raised to $351 at Guggenheim
• Neutral Sentiment: Short‑interest data reported for April appears inconsistent/erroneous (reads as 0 shares / NaN increase), so it’s unlikely to be a reliable driver of today’s action. (data entry)
• Neutral Sentiment: Media pieces highlighting Amgen’s profitability and recent TEPEZZA subcutaneous Phase‑3 topline results reinforce the company’s longer‑term value story but are incremental to near‑term price moves. Is Amgen One of the Most Profitable Value Stocks?
• Negative Sentiment: Morgan Stanley’s latest stance (equal‑weight, target raised only to $326) and other hold ratings emphasize limited near‑term upside vs. current levels — that analyst positioning is weighing on the stock. Morgan Stanley equal weight on Amgen

Analysts Set New Price Targets

A number of equities analysts recently issued reports on AMGN shares. Truist Financial raised their price target on Amgen from $318.00 to $319.00 and gave the stock a "hold" rating in a report on Thursday, January 8th. Morgan Stanley raised their price target on Amgen from $309.00 to $326.00 and gave the stock an "equal weight" rating in a report on Friday. Piper Sandler raised their price target on Amgen from $381.00 to $432.00 and gave the stock an "overweight" rating in a report on Wednesday, February 18th. Sanford C. Bernstein lowered Amgen from an "outperform" rating to a "market perform" rating and set a $335.00 price target on the stock. in a report on Tuesday, January 20th. Finally, Jefferies Financial Group started coverage on Amgen in a report on Tuesday, March 10th. They set a "hold" rating and a $350.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $355.84.

Amgen Price Performance

Shares of AMGN opened at $350.92 on Friday. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29. The stock's 50 day moving average is $363.87 and its two-hundred day moving average is $335.08. The firm has a market capitalization of $189.39 billion, a PE ratio of 24.66, a P/E/G ratio of 3.48 and a beta of 0.47. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts' consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. During the same quarter in the previous year, the company earned $5.31 EPS. The firm's revenue for the quarter was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen's payout ratio is currently 70.84%.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.